XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.
Saved in:
| Title: | XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial. |
|---|---|
| Authors: | Pan QZ; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.; Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China., Zhao JJ; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.; Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China., Liu L; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, PR China.; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, 300060, PR China.; Department of Biotherapy/Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, PR China., Zhang DS; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China., Wang LP; Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, PR China., Hu WW; Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, PR China.; Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, 213003, PR China.; Institute for Cell Therapy of Soochow University, Changzhou, Jiangsu, 213003, PR China., Weng DS; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.; Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China., Xu X; Department of Stem Cell & Regenerative Medicine, State Key Laboratory of Trauma, Burn and Combined Injury, Daping Hospital, Army Medical University, Chongqing, 400042, PR China., Li YZ; Imaging Diagnosis and Interventional Center, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China., Tang Y; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.; Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China., Zhang WH; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, PR China.; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, 300060, PR China.; Department of Biotherapy/Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, PR China., Li JY; Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, PR China., Zheng X; Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, PR China.; Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, 213003, PR China.; Institute for Cell Therapy of Soochow University, Changzhou, Jiangsu, 213003, PR China., Wang QJ; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.; Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China., Li YQ; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.; Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China., Xiang T; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China., Zhou L; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, PR China.; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, 300060, PR China.; Department of Biotherapy/Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, PR China., Yang SN; Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, PR China., Wu C; Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, PR China.; Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, 213003, PR China.; Institute for Cell Therapy of Soochow University, Changzhou, Jiangsu, 213003, PR China., Huang RX; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.; Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China., He J; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.; Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China., Du WJ; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, PR China.; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, 300060, PR China.; Department of Biotherapy/Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, PR China., Chen LJ; Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, PR China.; Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, 213003, PR China.; Institute for Cell Therapy of Soochow University, Changzhou, Jiangsu, 213003, PR China., Wu YN; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.; Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China., Xu B; Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, PR China.; Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, 213003, PR China.; Institute for Cell Therapy of Soochow University, Changzhou, Jiangsu, 213003, PR China., Shen Q; Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, PR China.; Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, 213003, PR China.; Institute for Cell Therapy of Soochow University, Changzhou, Jiangsu, 213003, PR China., Zhang Y; Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, PR China. yizhang@zzu.edu.cn., Jiang JT; Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, PR China. jiangjingting@suda.edu.cn.; Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, 213003, PR China. jiangjingting@suda.edu.cn.; Institute for Cell Therapy of Soochow University, Changzhou, Jiangsu, 213003, PR China. jiangjingting@suda.edu.cn., Ren XB; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, PR China. renxiubao@tjmuch.com.; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, 300060, PR China. renxiubao@tjmuch.com.; Department of Biotherapy/Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, PR China. renxiubao@tjmuch.com., Xia JC; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China. xiajch@mail.sysu.edu.cn.; Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China. xiajch@mail.sysu.edu.cn. |
| Source: | Signal transduction and targeted therapy [Signal Transduct Target Ther] 2024 Apr 03; Vol. 9 (1), pp. 79. Date of Electronic Publication: 2024 Apr 03. |
| Publication Type: | Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101676423 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-3635 (Electronic) Linking ISSN: 20593635 NLM ISO Abbreviation: Signal Transduct Target Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38565886 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Pan+QZ%22">Pan QZ</searchLink>; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.; Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.<br /><searchLink fieldCode="AU" term="%22Zhao+JJ%22">Zhao JJ</searchLink>; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.; Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.<br /><searchLink fieldCode="AU" term="%22Liu+L%22">Liu L</searchLink>; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, PR China.; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, 300060, PR China.; Department of Biotherapy/Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, PR China.<br /><searchLink fieldCode="AU" term="%22Zhang+DS%22">Zhang DS</searchLink>; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China.<br /><searchLink fieldCode="AU" term="%22Wang+LP%22">Wang LP</searchLink>; Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, PR China.<br /><searchLink fieldCode="AU" term="%22Hu+WW%22">Hu WW</searchLink>; Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, PR China.; Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, 213003, PR China.; Institute for Cell Therapy of Soochow University, Changzhou, Jiangsu, 213003, PR China.<br /><searchLink fieldCode="AU" term="%22Weng+DS%22">Weng DS</searchLink>; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.; Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.<br /><searchLink fieldCode="AU" term="%22Xu+X%22">Xu X</searchLink>; Department of Stem Cell & Regenerative Medicine, State Key Laboratory of Trauma, Burn and Combined Injury, Daping Hospital, Army Medical University, Chongqing, 400042, PR China.<br /><searchLink fieldCode="AU" term="%22Li+YZ%22">Li YZ</searchLink>; Imaging Diagnosis and Interventional Center, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.<br /><searchLink fieldCode="AU" term="%22Tang+Y%22">Tang Y</searchLink>; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.; Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.<br /><searchLink fieldCode="AU" term="%22Zhang+WH%22">Zhang WH</searchLink>; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, PR China.; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, 300060, PR China.; Department of Biotherapy/Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, PR China.<br /><searchLink fieldCode="AU" term="%22Li+JY%22">Li JY</searchLink>; Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, PR China.<br /><searchLink fieldCode="AU" term="%22Zheng+X%22">Zheng X</searchLink>; Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, PR China.; Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, 213003, PR China.; Institute for Cell Therapy of Soochow University, Changzhou, Jiangsu, 213003, PR China.<br /><searchLink fieldCode="AU" term="%22Wang+QJ%22">Wang QJ</searchLink>; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.; Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.<br /><searchLink fieldCode="AU" term="%22Li+YQ%22">Li YQ</searchLink>; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.; Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.<br /><searchLink fieldCode="AU" term="%22Xiang+T%22">Xiang T</searchLink>; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.<br /><searchLink fieldCode="AU" term="%22Zhou+L%22">Zhou L</searchLink>; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, PR China.; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, 300060, PR China.; Department of Biotherapy/Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, PR China.<br /><searchLink fieldCode="AU" term="%22Yang+SN%22">Yang SN</searchLink>; Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, PR China.<br /><searchLink fieldCode="AU" term="%22Wu+C%22">Wu C</searchLink>; Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, PR China.; Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, 213003, PR China.; Institute for Cell Therapy of Soochow University, Changzhou, Jiangsu, 213003, PR China.<br /><searchLink fieldCode="AU" term="%22Huang+RX%22">Huang RX</searchLink>; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.; Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.<br /><searchLink fieldCode="AU" term="%22He+J%22">He J</searchLink>; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.; Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.<br /><searchLink fieldCode="AU" term="%22Du+WJ%22">Du WJ</searchLink>; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, PR China.; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, 300060, PR China.; Department of Biotherapy/Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, PR China.<br /><searchLink fieldCode="AU" term="%22Chen+LJ%22">Chen LJ</searchLink>; Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, PR China.; Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, 213003, PR China.; Institute for Cell Therapy of Soochow University, Changzhou, Jiangsu, 213003, PR China.<br /><searchLink fieldCode="AU" term="%22Wu+YN%22">Wu YN</searchLink>; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.; Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China.<br /><searchLink fieldCode="AU" term="%22Xu+B%22">Xu B</searchLink>; Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, PR China.; Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, 213003, PR China.; Institute for Cell Therapy of Soochow University, Changzhou, Jiangsu, 213003, PR China.<br /><searchLink fieldCode="AU" term="%22Shen+Q%22">Shen Q</searchLink>; Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, PR China.; Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, 213003, PR China.; Institute for Cell Therapy of Soochow University, Changzhou, Jiangsu, 213003, PR China.<br /><searchLink fieldCode="AU" term="%22Zhang+Y%22">Zhang Y</searchLink>; Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, PR China. yizhang@zzu.edu.cn.<br /><searchLink fieldCode="AU" term="%22Jiang+JT%22">Jiang JT</searchLink>; Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, 213003, PR China. jiangjingting@suda.edu.cn.; Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu, 213003, PR China. jiangjingting@suda.edu.cn.; Institute for Cell Therapy of Soochow University, Changzhou, Jiangsu, 213003, PR China. jiangjingting@suda.edu.cn.<br /><searchLink fieldCode="AU" term="%22Ren+XB%22">Ren XB</searchLink>; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, PR China. renxiubao@tjmuch.com.; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, 300060, PR China. renxiubao@tjmuch.com.; Department of Biotherapy/Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, PR China. renxiubao@tjmuch.com.<br /><searchLink fieldCode="AU" term="%22Xia+JC%22">Xia JC</searchLink>; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China. xiajch@mail.sysu.edu.cn.; Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, PR China. xiajch@mail.sysu.edu.cn. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101676423%22">Signal transduction and targeted therapy</searchLink> [Signal Transduct Target Ther] 2024 Apr 03; Vol. 9 (1), pp. 79. <i>Date of Electronic Publication: </i>2024 Apr 03. – Name: TypePub Label: Publication Type Group: TypPub Data: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101676423 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2059-3635 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220593635%22">20593635 </searchLink><i>NLM ISO Abbreviation: </i>Signal Transduct Target Ther <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38565886 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41392-024-01788-2 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 79 Titles: – TitleFull: XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Pan QZ – PersonEntity: Name: NameFull: Zhao JJ – PersonEntity: Name: NameFull: Liu L – PersonEntity: Name: NameFull: Zhang DS – PersonEntity: Name: NameFull: Wang LP – PersonEntity: Name: NameFull: Hu WW – PersonEntity: Name: NameFull: Weng DS – PersonEntity: Name: NameFull: Xu X – PersonEntity: Name: NameFull: Li YZ – PersonEntity: Name: NameFull: Tang Y – PersonEntity: Name: NameFull: Zhang WH – PersonEntity: Name: NameFull: Li JY – PersonEntity: Name: NameFull: Zheng X – PersonEntity: Name: NameFull: Wang QJ – PersonEntity: Name: NameFull: Li YQ – PersonEntity: Name: NameFull: Xiang T – PersonEntity: Name: NameFull: Zhou L – PersonEntity: Name: NameFull: Yang SN – PersonEntity: Name: NameFull: Wu C – PersonEntity: Name: NameFull: Huang RX – PersonEntity: Name: NameFull: He J – PersonEntity: Name: NameFull: Du WJ – PersonEntity: Name: NameFull: Chen LJ – PersonEntity: Name: NameFull: Wu YN – PersonEntity: Name: NameFull: Xu B – PersonEntity: Name: NameFull: Shen Q – PersonEntity: Name: NameFull: Zhang Y – PersonEntity: Name: NameFull: Jiang JT – PersonEntity: Name: NameFull: Ren XB – PersonEntity: Name: NameFull: Xia JC IsPartOfRelationships: – BibEntity: Dates: – D: 03 M: 04 Text: 2024 Apr 03 Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 2059-3635 Numbering: – Type: volume Value: 9 – Type: issue Value: 1 Titles: – TitleFull: Signal transduction and targeted therapy Type: main |
| ResultId | 1 |
